EDMONTON, Sept. 5 /CNW/ - It is well known that many cancer types - or even the same cancer in different patients - show different sensitivities to a given therapeutic treatment. In earlier studies Cyplasin-SC(TM) has shown to be an efficient killer of many cancer cell types whereas normal human cells were left intact. An independent third party study conducted by Professor di Liegro, Department of Medicine of the University of Palermo, Italy, tested Cyplasin-SC(TM) on 5 melanoma cell lines derived from 5 different patients to determine if all melanoma cells were equally susceptible to Cyplasin-SC(TM) or if there were specific melanomas that did not respond to the drug. As a control to these experiments normal human cells were also exposed to the same concentrations of Cyplasin-SC(TM) used for the melanoma experiments.
